GlassScriptPhysician profile
Amanda J Holmquist
NPI 1114260759
$1,830.32
in general payments reported to CMS, 2019-2025
24 companies · $477 in 2025
The $477 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $106 · 2021: $12.37 · 2022: $355 · 2023: $506 · 2024: $235 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,217.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $472.45 | 2019-2025 | Myosure Tissue Removal Device, Novasure, Omni Hysteroscope |
| Abbvie INC. | $344.45 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $148.62 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $117.30 | 2023-2025 | Myfembree |
| Organon LLC | $110.24 | 2022-2024 | Nexplanon |
| Mayne Pharma Commercial LLC | $79.94 | 2022-2025 | |
| Therapeuticsmd, INC. | $69.45 | 2019-2022 | |
| Astellas Pharma US INC | $63.53 | 2023-2025 | Veozah |
| Vertex Pharmaceuticals Incorporated | $50.12 | 2025 | |
| Exeltis, USA INC. | $43.44 | 2022-2023 | Slynd |
| Acella Pharmaceuticals, LLC | $38.65 | 2024-2025 | NP Thyroid 60 |
| Ethicon US, LLC | $34.49 | 2022-2023 | Harmonic |
| Sanara Medtech INC. | $33.38 | 2024 | Celleraterx |
| Biogen, INC. | $32.31 | 2024-2025 | Zurzuvae |
| Servier Pharmaceuticals LLC | $28.19 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $23.43 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $22.55 | 2024 | Exparel |
| Amag Pharmaceuticals, INC. | $21.46 | 2019 | |
| Myriad Women'S Health, INC. | $21.18 | 2023 | Myrisk |
| Seqirus USA INC | $16.54 | 2025 | Fluad, Flucelvax |
| Lupin INC. | $16.03 | 2020 | |
| Smith+Nephew, INC. | $14.92 | 2025 | Pico |
| Millicent US INC | $14.48 | 2023 | Femring, Intrarosa |
| Boston Scientific Corporation | $13.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Holmquist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.